BioProtect

Company Overview

Snapshot

Founded in September 2004 by Shaul Shohat, BioProtect operates with 51–200 employees. The company has raised a total of $62.25M across 10 funding rounds from 19 investors. In May 2026, BioProtect was acquired by Olympus Corporation.

Business overview

BioProtect is a Health Tech & Life Sciences company specializing in medical devices and treatment therapeutics. The company develops a proprietary technology platform for biodegradable balloons, designed for various clinical applications including radiation oncology protection, aesthetics, and general surgery. Its flagship product, the BioProtect/ProSpace Balloon System, serves as a spacer to protect healthy tissue during prostate cancer radiotherapy. BioProtect's products are commercially available in Europe and are undergoing clinical studies in the United States for FDA approval, targeting the healthcare market, specifically providers.

Strategic signal

The acquisition of BioProtect by Olympus Corporation in May 2026 for $270 million signifies a major strategic move in the medical device sector. This acquisition validates BioProtect's innovative biodegradable balloon technology for prostate cancer treatment and indicates a growing interest from large corporate entities in advanced solutions for radiation therapy. For investors, this signals the potential for significant returns in the health tech space, particularly for companies addressing critical unmet clinical needs with proven technology.

Company Intelligence Q&A

What was the most significant recent corporate development for BioProtect?

In May 2026, BioProtect was acquired by Olympus Corporation for $270 million, marking a significant exit for the company and its investors.

When did BioProtect complete patient enrollment for its IDE pivotal study of the ProSpace Balloon Spacer?

BioProtect noted the completion of patient enrollment for its IDE pivotal study of the ProSpace Balloon Spacer in June 2021.

Which investors participated in BioProtect's funding round in September 2020?

In September 2020, BioProtect received funding from investors including Almeda Ventures and Medtronic.

When did BioProtect receive Investigational Device Exemption (IDE) approval from the FDA?

BioProtect received Investigational Device Exemption (IDE) approval from the FDA in January 2018.